We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+12.85%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
Cap. Flow
-$5.1M
Cap. Flow %
-1.78%
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$16.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
ESTA icon
Establishment Labs
ESTA
+$6.8M
5
KURA icon
Kura Oncology
KURA
+$6.54M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.8M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
3
MRK icon
Merck
MRK
+$12.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.75M
5
BLU
BELLUS Health Inc.
BLU
+$6.35M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
26
DELISTED
SpringWorks Therapeutics
SWTX
$3.41M 1.19%
+130,000
New +$3.42M
VTYX
27
DELISTED
Ventyx Biosciences
VTYX
$3.3M 1.15%
100,696
-159,312
-61% -$5.49M
VRDN icon
28
CALL
Viridian Therapeutics
VRDN
$2.09B
$3.1M 1.08%
130,400
+29,900
+30% +$767K
RETA
29
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.97M 1.04%
+29,105
New +$2.75M
CLDX icon
30
Celldex Therapeutics
CLDX
$2.77B
$2.95M 1.03%
87,031
+37,031
+74% +$1.25M
KYNB
31
Kyntra Bio
KYNB
$29.1M
$2.65M 0.93%
+39,332
New +$16.3M
KYNB
32
PUT
Kyntra Bio
KYNB
$29.1M
$2.65M 0.93%
+39,332
New +$16.3M
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.49B
$2.32M 0.81%
60,376
-29,624
-33% -$1.18M
THRX
34
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.24M 0.78%
240,244
+142,023
+145% +$1.4M
SYRE icon
35
Spyre Therapeutics
SYRE
$8.64B
$2.21M 0.77%
+196,000
New +$929K
VINC
36
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.94M 0.68%
74,639
– –
LIAN
37
DELISTED
LianBio American Depositary Shares
LIAN
$1.83M 0.64%
800,676
+150,676
+23% +$346K
CABA icon
38
Cabaletta Bio
CABA
$458M
$1.61M 0.56%
+125,000
New +$1.36M
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
$1.6M 0.56%
178,292
-30,000
-14% -$277K
ADCT icon
40
ADC Therapeutics
ADCT
$164M
$1.29M 0.45%
600,000
– –
WHWK
41
Whitehawk Therapeutics
WHWK
$189M
$1.28M 0.45%
+187,675
New +$1.46M
ALDX icon
42
Aldeyra Therapeutics
ALDX
$104M
$1.26M 0.44%
+150,000
New +$1.48M
ALPN
43
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.22M 0.43%
118,891
-129,000
-52% -$1.16M
NAMS icon
44
NewAmsterdam Pharma
NAMS
$3.52B
$1.19M 0.42%
+100,000
New +$1.33M
ARAV
45
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.09M 0.38%
+861,200
New +$1.4M
IFRX icon
46
InflaRx
IFRX
$270M
$1.07M 0.37%
+240,200
New +$1.08M
MLYS icon
47
Mineralys Therapeutics
MLYS
$2.35B
$1.07M 0.37%
62,500
– –
NRIX icon
48
Nurix Therapeutics
NRIX
$2.37B
$999K 0.35%
100,000
-50,000
-33% -$510K
BCAB icon
49
BioAtla
BCAB
$6.37M
$975K 0.34%
6,500
– –
KYNB
50
CALL
Kyntra Bio
KYNB
$29.1M
$918K 0.32%
+13,600
New +$5.62M
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors's Q2 2023 filing shows 24 new, 16 increased, 16 reduced and 27 closed positions. Its largest new stake was Kyntra Bio: 39,332 shares worth $2.65M. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier.

  • Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
  • Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
  • Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
  • Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
  • Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.